Breast Cancer

Latest News

Health equity text | Image Credit: Andrii - stock.adobe.com
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

November 19th 2024

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

Medicare Expansion | Image Credit: wladimir1804- stock.adobe.com
Breast Cancer Outcomes Improved in States With Medicaid Expansion

October 24th 2024

FDA Approved
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

October 11th 2024

Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
5 Things to Know Before a Breast Screening

October 11th 2024

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Advancing Breast Cancer Care With HER2-Targeted Therapies

October 10th 2024

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

AJMC® in the Press, May 1, 2020
May 1st 2020

AJMC® in the Press, May 1, 2020

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Phase 3 EMBRACA Findings Suggest No Overall Survival Benefit With Talazoparib in Advanced BRCA-Mutated Breast Cancer
April 28th 2020

Phase 3 EMBRACA Findings Suggest No Overall Survival Benefit With Talazoparib in Advanced BRCA-Mutated Breast Cancer

Matthew Gavidia
In new data from the phase 3 EMBRACA trial presented yesterday at the American Association for Cancer Research annual meeting, researchers found that PARP inhibitor talazoparib exhibited no statistically significant benefit in the secondary end point of overall survival in patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Does Posttreatment Weight Loss Equate to Improved Quality of Life Among Survivors of Breast Cancer?
April 27th 2020

Does Posttreatment Weight Loss Equate to Improved Quality of Life Among Survivors of Breast Cancer?

Maggie L. Shaw
An international team of investigators recently tried to answer this question, focusing on women with diagnosed early-stage disease and considered obese, with a body mass index above 30 kg/m2.
FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer
April 22nd 2020

FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer

Gianna Melillo
The FDA granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) as the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) that has spread to other parts of the body.
Can Melatonin Alleviate Symptoms of Cognitive Impairment in Patients With Breast Cancer?
April 22nd 2020

Can Melatonin Alleviate Symptoms of Cognitive Impairment in Patients With Breast Cancer?

Maggie L. Shaw
Cognitive impairment is a well-documented adverse effect of treatment from breast cancer. Complications from it can appear soon after treatment has begun or far down the road.
How Are Breast Cancer and Obesity Related? Possible New Link Discovered
April 18th 2020

How Are Breast Cancer and Obesity Related? Possible New Link Discovered

Maggie L. Shaw
There is a greater risk of hormone receptor–positive breast cancer if a patient is obese. Researchers from the University of Louisville have discovered a possible new link between obesity and a greater risk for developing breast cancer: adipose fatty acid binding protein.
Oncology Groups Issue Preliminary COVID-19 Triage Guidelines for Breast Cancer
April 16th 2020

Oncology Groups Issue Preliminary COVID-19 Triage Guidelines for Breast Cancer

Maggie L. Shaw
Several prominent oncology organizations, including the National Comprehensive Cancer Network and the Commission on Cancer, have joined forces to issue preliminary guidelines on how to treat patients with breast cancer during the coronavirus disease 2019 (COVID-19) pandemic.
Regular Exercise Confers a Significant Survival Benefit Among Patients With Breast Cancer
April 10th 2020

Regular Exercise Confers a Significant Survival Benefit Among Patients With Breast Cancer

Maggie L. Shaw
Meeting HHS’ minimum requirements for daily and weekly exercise reduced breast cancer recurrence and mortality among patients with high-risk breast cancer undergoing chemotherapy. This benefit was even seen in patients who had not met these requirements before their diagnosis.
Study Results Show Pembrolizumab Plus Chemotherapy May Be Effective in Patients With TNBC
April 9th 2020

Study Results Show Pembrolizumab Plus Chemotherapy May Be Effective in Patients With TNBC

Maggie L. Shaw
The standard therapy for triple-negative breast cancer (TNBC) remains chemotherapy, despite a dismal prognosis due to lack of estrogen and progesterone hormone receptors, as well as HER2 receptors. Targeted therapies for this difficult-to-treat, often aggressive, subtype of breast cancer remain elusive.
White Blood Cell Profile Linked to Greater Breast Cancer Risk
April 4th 2020

White Blood Cell Profile Linked to Greater Breast Cancer Risk

Maggie L. Shaw
What can be done to further delineate the risk factors associated with breast cancer to increase prevention efforts across the board? The key may lie in the white blood cells that circulate in the blood, particularly leukocytes and monocytes.
Genetic Testing May Benefit Older Women With Breast Cancer
April 2nd 2020

Genetic Testing May Benefit Older Women With Breast Cancer

Maggie L. Shaw
The 2 main criteria that warrant genetic testing for breast cancer in women are age and having a family history of cancer. Postmenopausal women without any hereditary risk factors, however, often do not undergo genetic testing for the disease.
AB MRI Shown to Improve Cancer Detection Rate in Women With Dense Breast Tissue
March 26th 2020

AB MRI Shown to Improve Cancer Detection Rate in Women With Dense Breast Tissue

Maggie L. Shaw
Not all women with dense breast tissue have a high risk of breast cancer, but they all have an increased risk compared with women who have average tissue density. Can this patient population benefit from screening with abbreviated breast magnetic resonance imaging (AB MRI) over digital breast tomosynthesis?
What Is the Relationship Between Hormone-Modulating Therapies and Incidence of Neurodegenerative Diseases?
March 24th 2020

What Is the Relationship Between Hormone-Modulating Therapies and Incidence of Neurodegenerative Diseases?

Gianna Melillo
Two hormone-modulating breast cancer therapies (HMTs), tamoxifen and steroidal aromatase inhibitors, were associated with a decrease in the number of women who received a diagnosis of a neurodegenerative disease, according to a study published in JAMA Network Open. Specifically, the 2 HMTs were associated with significant decreases in diagnoses of Alzheimer disease and dementia.
Does Treatment Begin and End Sooner With Neoadjuvant or Adjuvant Chemotherapy?
March 13th 2020

Does Treatment Begin and End Sooner With Neoadjuvant or Adjuvant Chemotherapy?

Maggie L. Shaw
Patients who undergo neoadjuvant chemotherapy tend to be younger, with larger tumors and greater nodal involvement. But differences in their 30- and 90-day mortality rates compared with those of patients treated adjuvantly are clinically insignificant.
Did Medicaid Expansion Impact Cancer Diagnosis Rates?
March 12th 2020

Did Medicaid Expansion Impact Cancer Diagnosis Rates?

Rachel Lutz
Investigators tracked time to treatment for 3 types of cancer in states that expanded Medicaid coverage on January 1, 2014, comparing rates before and after the expansion. Patients with new diagnoses of invasive breast, colon, or lung cancers aged 40 to 64 years were included in the analysis.
Does Method of Communication Influence a Woman's Understanding of Familial Breast Cancer Risk?
March 5th 2020

Does Method of Communication Influence a Woman's Understanding of Familial Breast Cancer Risk?

Maggie L. Shaw
Thirty-seven percent of women prefer to receive their lifetime risk of breast cancer through numbers and words, while 73% prefer a combination of lifetime and 10-year age-related risk.
PAPER OF THE WEEK: Mammogram Practices Don't Match the Evidence
March 1st 2020

PAPER OF THE WEEK: Mammogram Practices Don't Match the Evidence

Mary Caffrey
Of the women in the 2017 study over age 75, 63% had a mammogram.
Mammography Screening Improves Outcomes Among African American and White American Patients With TNBC
February 29th 2020

Mammography Screening Improves Outcomes Among African American and White American Patients With TNBC

Rachel Lutz
Screening mammography is important for reducing race- and ethnicity-associated triple-negative breast cancer (TNBC) disparities among African American and white American patients. At present, there is a 40% higher mortality rate among African American women compared with white American women.
Mammography in Women Older Than 75 Does Not Confer an Additional Survival Benefit
February 25th 2020

Mammography in Women Older Than 75 Does Not Confer an Additional Survival Benefit

Maggie L. Shaw
Recommendations abound for when women at average risk for breast cancer should begin yearly mammography screening, ranging from age 40 to 50. Questions remain, however, on the optimal age at which to stop. However, with over 50% of women older than age 75 still undergoing mammography, is there a truly safe age at which to stop what has been shown to be a life-saving practice if it does not decrease their mortality from breast cancer?
Longer Time to First Treatment Beneficial for Breast Cancer
February 22nd 2020

Longer Time to First Treatment Beneficial for Breast Cancer

Rachel Lutz
When time to first treatment ranged from 31 to 90 days for patients with breast cancer, doctors had more time for extensive diagnostic workups without compromising survival rates.
Is Targeted Treatment in the Future for Triple-Negative Breast Cancer?
February 15th 2020

Is Targeted Treatment in the Future for Triple-Negative Breast Cancer?

Maggie L. Shaw
The 5-year survival rate for triple-negative breast cancer (TNBC) is about 77%. The recurrence rate is highest in the first 3 years after treatment, but falls off at the 5-year mark—although the survival rate at this time point tends to be lower. Because TNBC cells lack the hormone receptors for estrogen and progesterone and do not overexpress the human epidermal growth factor receptor 2 gene, treatment often involves chemotherapy, radiation, and surgery. Targeted treatments are not used with TNBC.
CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers
January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey
CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.
Dr Banu Arun on Technologies to Expand Access to Genetic Counseling
December 15th 2019

Dr Banu Arun on Technologies to Expand Access to Genetic Counseling

There are new technologies that allow for genetic counseling services through which the provider does not even need to get that involved in the process, said Banu Arun, MD, medical oncologist, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center.
Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies
December 14th 2019

Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies

Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Site Logo
December 14th 2019

Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive Care

Matthew Gavidia
Two abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for patients with early-stage and metastatic breast cancer.
Site Logo
December 14th 2019

Oral Paclitaxel Reveals Superior Confirmed Response, Survival in Patients With Metastatic Breast Cancer, Compared With IV Paclitaxel

Matthew Gavidia
In phase 3 trial results presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, oral paclitaxel with encequidar, the first orally administered paclitaxel, was shown to exhibit superior confirmed response and survival with less neuropathy for patients with metastatic breast cancer compared with intravenous (IV) paclitaxel.
Dr Rita Nanda Discusses What Findings of I-SPY2 Mean for Future Breast Cancer Treatments
December 13th 2019

Dr Rita Nanda Discusses What Findings of I-SPY2 Mean for Future Breast Cancer Treatments

Rita Nanda, MD, associate professor, medicine, The University of Chicago Medicine, outlines the design of the I-SPY2 clinical trial and what the results have been so far.
Dr Corey Speers on Challenges Adopting Personalized Radiation Therapy
December 13th 2019

Dr Corey Speers on Challenges Adopting Personalized Radiation Therapy

Ensuring that prognostic or predictive tests to help make decisions regarding radiation therapy are accurate and clinically validated remains a challenge, said Corey Speers, MD, PhD, assistant professor, radiation oncology, University of Michigan.
Site Logo
December 13th 2019

Age Associated With Benefit Derived From Chemotherapy for Women With Luminal Breast Cancer, MINDACT Trial Finds

Matthew Gavidia
Data from the MINDACT trial revealed that among women with luminal breast cancers (hormone receptor–positive, HER2-negative by local pathology) with a high clinical risk and low genomic risk, those aged 40 to 50 years had a greater, but insignificant, benefit from chemotherapy than patients older than 50.
Dr Nadine Tung Discusses When to Refer Patients for Germline Testing
December 13th 2019

Dr Nadine Tung Discusses When to Refer Patients for Germline Testing

The bar for who should get genetic testing for breast cancer keeps getting lowered, and oncologists have to keep informed about which results should trigger a referral for germline testing, said Nadine Tung, MD, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, and associate professor, medicine, Harvard Medical School.
<1
...
6789101112>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo